IQVIA drops as investors revisit soft 2026 EPS outlook and higher interest expense
IQVIA shares fell about 3.3% to $163.16 as investors refocused on weaker-than-expected 2026 EPS guidance issued with Q4 2025 results. The company projected 2026 adjusted diluted EPS of $12.55–$12.85, below prior Street expectations, with higher net interest expense a key headwind.
1) What’s moving the stock
IQVIA Holdings (IQV) traded lower in the latest session, extending pressure that began after the company’s Q4 2025 report and outlook reset. The key overhang is IQVIA’s full-year 2026 adjusted diluted EPS guidance range of $12.55 to $12.85, which came in below prior consensus and triggered a valuation reset for the stock.
2) The numbers investors are reacting to
Alongside its Q4 2025 results, IQVIA guided 2026 revenue to $17.159 billion to $17.359 billion and adjusted diluted EPS to $12.55 to $12.85. Management also flagged net interest expense of roughly $760 million for 2026 (about $80 million higher versus 2025), which investors have treated as a meaningful drag on earnings leverage even as the company highlights demand, bookings, and backlog strength.
3) What to watch next
With guidance now the focal point, traders will look for incremental datapoints that either validate or challenge the 2026 earnings range—especially around margin durability, demand in clinical services, and the cost of financing. Investors will also monitor management’s conference commentary and investor materials for any updated assumptions around interest expense, share repurchases, and the pace of growth across IQVIA’s services and analytics offerings.